Ascendis Bone Drug Patent Portfolio
Ascendis Bone owns 1 orange book drug protected by 9 US patents Given below is the list of Ascendis Bone's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12403182 | Liquid Pharmaceutical Formulations Of Pth Conjugates | 12 Nov, 2042 | Active |
| US11590207 | Dosage regimen for a controlled-release PTH compound | 28 Sep, 2037 | Active |
| US11759504 | PTH compounds with low peak-to-trough ratios | 28 Sep, 2037 | Active |
| US11857603 | PTH compounds with low peak-to-trough ratios | 28 Sep, 2037 | Active |
| US11890326 | Controlled-release PTH compound | 28 Sep, 2037 | Active |
| US11918628 | Controlled-release PTH compound | 28 Sep, 2037 | Active |
| US12295989 | Controlled-release PTH compound | 28 Sep, 2037 | Active |
| US12453778 | Incremental Dose Finding In Controlled-Release Pth Compounds | 28 Sep, 2037 | Active |
| US8906847 | Prodrug comprising a drug linker conjugate | 30 Apr, 2031 | Active |
Latest Legal Activities on Ascendis Bone's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ascendis Bone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Application Is Considered Ready for Issue | 03 Oct, 2025 | US12453778 |
| Dispatch to FDC | 03 Oct, 2025 | US12453778 |
| Email Notification | 02 Oct, 2025 | US12453778 |
| Mail Response to 312 Amendment (PTO-271) | 02 Oct, 2025 | US12453778 |
| Letter Accepting Correction of Inventorship Under Rule 1.48 | 01 Oct, 2025 | US12453778 |
| Email Notification | 01 Oct, 2025 | US12453778 |
| Filing Receipt - Updated | 01 Oct, 2025 | US12453778 |
| Response to Amendment under Rule 312 | 27 Sep, 2025 | US12453778 |
| Issue Fee Payment Received | 26 Sep, 2025 | US12453778 |
| Issue Fee Payment Verified | 26 Sep, 2025 | US12453778 |
| Response to Reasons for Allowance | 26 Sep, 2025 | US12453778 |
| Pubs Case Remand to TC | 26 Sep, 2025 | US12453778 |
| Miscellaneous Incoming Letter | 25 Sep, 2025 | US12453778 |
| Supplemental Papers - Oath or Declaration | 25 Sep, 2025 | US12453778 |
| Recordation of Patent eCertificate of Correction | 09 Sep, 2025 | US12295989 |
Ascendis Bone's Family Patents
Ascendis Bone Drug List
Given below is the complete list of Ascendis Bone's drugs and the patents protecting them.
1. Yorvipath
Yorvipath is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12403182 | Liquid Pharmaceutical Formulations Of Pth Conjugates |
12 Nov, 2042
(16 years from now)
| Active |
| US11590207 | Dosage regimen for a controlled-release PTH compound |
28 Sep, 2037
(11 years from now)
| Active |
| US11759504 | PTH compounds with low peak-to-trough ratios |
28 Sep, 2037
(11 years from now)
| Active |
| US11857603 | PTH compounds with low peak-to-trough ratios |
28 Sep, 2037
(11 years from now)
| Active |
| US11890326 | Controlled-release PTH compound |
28 Sep, 2037
(11 years from now)
| Active |
| US11918628 | Controlled-release PTH compound |
28 Sep, 2037
(11 years from now)
| Active |
| US12295989 | Controlled-release PTH compound |
28 Sep, 2037
(11 years from now)
| Active |
| US12453778 | Incremental Dose Finding In Controlled-Release Pth Compounds |
28 Sep, 2037
(11 years from now)
| Active |
| US8906847 | Prodrug comprising a drug linker conjugate |
30 Apr, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yorvipath's drug page